Compare Avantis US Small Cap Value ETF (AVUV) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avantis US Small Cap Value ETF vs Recursion Pharmaceuticals Inc — how do they compare? Avantis US Small Cap Value ETF trades at $127.49, while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.81B). The key difference: Avantis US Small Cap Value ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AVUV | RXRX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $128.74 | $6.79 |
52-Week Low | $93.93 | $2.84 |
Market Cap | — | $1.81B |
Enterprise Value | — | $1.33B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Avantis US Small Cap Value ETF
AVUV is an actively managed ETF that targets small-cap value companies in the United States. It uses a systematic, rules-based process to identify firms with low valuations and high profitability, aiming to capture the historical premiums of 'size' and 'value' while filtering for financial quality.
Read more on AVUV →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
